IonQ reaches 1,000 patents milestone with new quantum computing grants
In a recent transaction, HiTron Systems Inc., a significant shareholder in Exicure , Inc. (NASDAQ:XCUR), acquired a substantial number of shares in the company. On December 26, 2024, HiTron Systems purchased 2.9 million shares of Exicure’s common stock at a price of $3.00 per share. Since then, XCUR’s stock has surged significantly, now trading at $13.91, reflecting the company’s remarkable 346% return over the past year and 265% gain in the last six months. This acquisition, valued at $8.7 million, increased HiTron Systems’ total holdings to approximately 3.33 million shares. The transaction was executed directly by HiTron Systems, with Andy Yoo, CEO, signing off on the filing. According to InvestingPro analysis, XCUR currently has a market capitalization of $84.72M and is trading above its Fair Value, with high price volatility typical for biotechnology stocks. Investors can access 12 additional exclusive ProTips and comprehensive financial metrics through InvestingPro’s advanced analytics platform.
In other recent news, Exicure, Inc. has announced several key developments. The company recently secured an Australian patent for a novel cancer treatment method, enhancing its intellectual property portfolio. This patent supports Exicure’s ongoing Phase 2 clinical trial, which explores a combination treatment for multiple myeloma. Additionally, Exicure confirmed it has met Nasdaq’s minimum stockholders’ equity requirement, allowing it to maintain its listing on the Nasdaq Capital Market. This follows a period of financial restructuring and compliance efforts, including a significant transaction with HiTron Systems Inc. that brought in $8.7 million. The company has also seen changes in its leadership, with Jiyoung Hwang and Paul Kang resigning from the Board of Directors, while new board members Chang Keun Choi and Minwoo Kang have joined the Audit Committee. These board transitions coincide with Andy Yoo’s recent appointment as CEO. Exicure continues to explore strategic alternatives to maximize shareholder value amidst these changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.